The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2018 | Using MRD to guide MM treatment
Measurable residual disease (MRD) analysis is becoming increasingly commonplace as a prognostic indicator and tool for guiding the management of multiple myeloma (MM) and other hematological malignancies. Here, Nikhil Munshi, MD, of the Dana-Farber Cancer Institute, Boston, MA, discusses how MRD can be used both as a surrogate for other outcome indicators like progression-free and overall survival, and for treatment guidance. He elaborates on this concept, suggesting that MRD negative patients could avoid aggressive treatments like stem cell transplants, and that with further research, perhaps even maintenance therapy could be avoided or reduced. This video was recorded at the 23rd Congress of European Hematology Association (EHA) 2018, held in Stockholm, Sweden.
